Lonza
Biologics, small-molecule apis and cell and gene therapy manufacturing.
Lonza manufactures biologics, small-molecule APIs and cell and gene therapy manufacturing from its Basel operations. The company supplies healthcare systems, laboratories, OEM partners or regulated export customers across its listed primary markets.
- Type
- Manufacturer
- Location
- Basel, Switzerland
- Founded
- 1897
- Website
- lonza.com
- Categories
- Medical & Healthcare Supplies, Chemicals & Plastics
- Markets
- Switzerland, United States, Germany, Singapore
Verified facts
- certificate-page-on-site (amber), checked 2026-08-11 Company's own certification page
- domain-registered (green), checked 2026-08-02 Domain registry record
- web-presence-since (green), checked 2026-08-03 Internet Archive (Wayback)
- operating-permit (green), checked 2026-08-24 SHAB, Swiss Official Gazette of Commerce
- lei-active (green), checked 2026-07-21 GLEIF
- sanctions-clear (green), checked 2026-07-21 OpenSanctions
- registry-active-global (green), checked 2026-07-21 Zefix (Swiss commercial registry)
Claimed certifications
- Good Manufacturing Practice
- ISO 9001, Quality Management IAF CertSearch
Import rules for these goods
- Medical devices sold in the EU must carry CE marking under the Medical Device Regulation (EU) 2017/745, with a conformity assessment matched to the device risk class. European Commission (MDR)
- For the US market, the maker must have an FDA device establishment registration and product listing; most instruments also need 510(k) premarket clearance. US FDA (devices)
- Chemical substances imported into the EU above 1 tonne/year must be REACH-registered. ECHA (REACH)